Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

GCAC to participate in study of medical cannabis effects on mental health

Stockhouse Editorial
0 Comments| March 28, 2018

{{labelSign}}  Favorites
{{errorMessage}}

Global Cannabis Applications Corp. (CSE: C.APP, OTCQB: FUAPF, Forum) said Wednesday it will participate in a medical cannabis study on the effects of cannabis on mental health conducted by Dr. Alasdair Barr.

The study, to be conducted at the University of British Columbia, will be applied using semi-structured clinical interviews with instruments commonly applied to clinical trials in order to investigate a population of people in Vancouver, B.C, who suffer from metal health issues and choose to self-medicate with medical cannabis.

More information can be found here.

Global Cannabis was in the news recently when it announced the launch of Global Cannabis Apps Corp. (GCAC), a private Australian company held 61% by Global Cannabis, which in turn is based in Vancouver.

FULL DISCLOSURE: Global Cannabis Applications Corp. is a paid client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company